Company Overview
Zentek Ltd. is a specialized entity focused on the research and development of graphene and related nanomaterials within the Canadian market. The company operates specifically within the Healthcare sector, functioning in the Medical Instruments & Supplies industry, which positions it to leverage advanced material science for medical applications. As a micro-cap entity, Zentek Ltd. maintains a market capitalization of $57.86M and employs a workforce of 18 individuals to support its operations. The company generates annual revenue of $942,877, indicating a very small scale relative to established peers in the medical supply chain. This valuation and revenue profile suggests the company is in an early stage of commercialization or is heavily reliant on niche R&D contracts rather than broad market distribution. The combination of a low employee count and modest revenue underscores the high-risk, high-research nature of developing proprietary technologies like the ZenGUARD brand coatings. Consequently, the company's current financial footprint reflects a strategic focus on intellectual property development rather than immediate large-scale profitability or market dominance.
Financial Health
Zentek Ltd. reported a revenue of $942,877 over the trailing twelve months, yet this income is vastly outweighed by a net loss of $-8,081,361, revealing a cost structure where expenses significantly exceed total revenue generation. The company also reports an EBITDA of $-8,374,869, indicating that even before financing costs and non-cash items, the core operations are generating substantial negative cash earnings. The free cash flow stands at $-1,694,322, which signifies a lack of financial flexibility and an ongoing burn rate that must be funded by external capital sources or existing reserves. Analyzing the margins shows a gross margin of 50.5%, suggesting that the cost of goods sold is managed reasonably well relative to sales, though this is insufficient to cover overheads. The operating margin is a staggering -4155.2%, while the profit margin is recorded as 0.0%, both figures highlighting extreme operational inefficiencies or one-time costs that have eroded bottom-line performance. In terms of liquidity, the company holds $1.80M in cash against $1.90M in debt, resulting in a debt-to-equity ratio of 15.40, which indicates a highly leveraged balance sheet where liabilities nearly equal equity. Despite the high leverage, the current ratio is 1.00, implying that the company's current assets exactly match its current liabilities, leaving no buffer for short-term liquidity shocks. Furthermore, the return on equity is -56.6% and the return on assets is -30.1%, metrics that reveal management has not yet achieved effectiveness in generating returns for shareholders or utilizing asset bases profitably.
Valuation Assessment
The company has neither a trailing P/E ratio nor a forward P/E ratio available, as both are listed as N/A, which implies that traditional earnings-based valuation models cannot be applied due to the absence of positive net income. The price-to-book ratio is 6.48, indicating that the market is valuing the company at a significant premium over its net asset value, likely reflecting the perceived value of its intangible graphene-based intellectual property. The price-to-sales ratio is 61.36, a figure that suggests investors are willing to pay a high multiple of revenue, often seen in early-stage biotech or material science firms where future revenue potential outweighs current profitability. The EV/EBITDA stands at -6.92, a negative multiple that further reinforces the company's current inability to generate earnings before interest, taxes, depreciation, and amortization. The 52-week high is $1.84 and the 52-week low is $0.52, meaning the current trading price sits somewhere within this wide range, reflecting high volatility in investor sentiment. With a beta of 0.30, the stock exhibits low volatility relative to the broader market, suggesting that price movements are less sensitive to general market shifts, though the wide range between the high and low indicates significant intraperiod price swings.
Growth & Income
Zentek Ltd. demonstrated a revenue growth rate of 73.1% year-over-year, while earnings growth is N/A due to continued net losses, implying that top-line expansion is occurring without a corresponding improvement in profitability. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm reinvests all available earnings, or rather, all capital, back into its research and development activities rather than distributing income to shareholders. This reinvestment strategy is typical for companies in the research phase where capital expenditure on graphene technology development takes precedence over income distribution. The overall growth and income profile presents a classic high-growth, negative-income scenario where the primary metric for investors is the acceleration of revenue rather than current cash returns.